FILTER

Refine your search with the following facets to narrow down your results.

9 Current news of Berna Biotech

Crucell Sells Stake in Pevion Biotech

16-Nov-2007 - Crucell N.V. announced that Berna Biotech AG, its wholly owned subsidiary, has sold all the 2.9 million shares it owned in Pevion Biotech Ltd, Bern (Switzerland) to other shareholders of Pevion Biotech. This number of shares represents 36 percent of Pevion Biotech's capital and results in net ...

Crucell Switzerland

Berna Biotech to divest its veterinary business Gräub AG

10-Apr-2006 - Berna Biotech announced that it has reached agreement on the sale of all its shares in the veterinary pharmaceuticals production company Dr. E. Gräub AG. The company will become a subsidiary of VETINVEST GmbH, a German company investing in the field of veterinary medicines. Berna decided to sell ...

Crucell to sell Rhein Biotech GmbH to Dynavax

29-Mar-2006 - Crucell N.V. announced plans to divest biopharmaceutical and vaccine manufacturer Rhein Biotech GmbH in a cash transaction. Rhein Biotech GmbH is part of Rhein Biotech N.V., a company 93% owned by Berna Biotech AG. Berna Biotech was recently acquired by Crucell N.V. Rhein Biotech GmbH is ...

Crucell Germany

Crucell's Exchange Offer for Berna Biotech successful

25-Jan-2006 - The Board of Berna Biotech AG announced that until the end of the regular offer period a large majority of the shareholders of Berna has followed its recommendation and accepted the Public Exchange Offer by Crucell N.V. for all outstanding Berna shares. On January 20, 2005, at 16.00 hours CET, ...

Crucell

Berna Biotech shareholders created the prerequisite to accept the public exchange offer of Crucell

13-Jan-2006 - The extraordinary general meeting of Berna Biotech, held in Berne, created the prerequisite to accept the public exchange offer of Crucell. It approved with about 90 percent of the represented shares the removal of the transfer restrictions. In addition, the shareholder's meeting elected Dr. ...

Crucell

Crucell Shareholders Approve Exchange Offer for Berna Biotech

12-Jan-2006 - Crucell N.V. announced that the General Meeting of Shareholders has approved the exchange offer for Berna Biotech A.G. in accordance with Section 2:107a of the Dutch Civil Code. If all shareholders of Berna tender their shares and the exchange offer is declared successful, Crucell will issue up ...

Crucell

Crucell and Berna Biotech: Together creating the leading independent vaccine company

05-Dec-2005 - Crucell and Berna Biotech jointly announced that Crucell plans to launch a recommended all share offer for the shares of Berna at an exchange ratio of 0.447 shares of Crucell for each Berna share. The offer values Berna at CHF 15.72 per Berna share based on the closing price of Crucell, ...

Aventis Chiron Crucell +1

Solvay and Berna Biotech sign a license agreement for vaccine against Pseudomonas aeruginosa in Cystic Fibrosis patients

04-Aug-2005 - Solvay Pharmaceuticals and Berna Biotech Ltd announced that they have signed a commercialization and license agreement for Aerugen®, a vaccine for the prevention of Pseudomonas aeruginosa (PA) infection in Cystic Fibrosis (CF) patients. The agreement complements Solvay Pharmaceuticals' CF product ...

cystic fibrosis license agreements Orphan Drug Designation +2

Dynavax Technologies and Berna Biotech Announce Collaboration

06-Nov-2003 - Dynavax Technologies Corporation and Berna Biotech Ltd. today announced execution of a license and supply agreement under which Berna has granted Dynavax a worldwide, non-exclusive right to utilize Berna's hepatitis B surface antigen, HBsAg, in Dynavax's programs for the development of hepatitis ...

yeasts